Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a stable profit growth with an accelerated layout in innovative drugs, maintaining a "Buy" rating. In H1 2025, the company achieved revenue of 7.898 billion yuan (down 4.08% year-on-year) and a net profit attributable to shareholders of 785 million yuan (up 1.10%) [5][6] - The company has a strong focus on respiratory diseases, with over 10 innovative drugs in the pipeline, and is making significant progress in clinical trials for various treatments [6] Financial Summary - In H1 2025, the company's gross margin was 62.21% (down 1.10 percentage points), and the net profit margin was 22.33% (up 1.73 percentage points) [5] - The company expects net profits attributable to shareholders to be 1.463 billion yuan, 1.568 billion yuan, and 1.715 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 0.80 yuan, 0.86 yuan, and 0.94 yuan per share [5][8] - The current stock price corresponds to a PE ratio of 16.1, 15.0, and 13.7 for the years 2025, 2026, and 2027 respectively [5] Research and Development - The company has made multiple breakthroughs in research and development, particularly in the respiratory field, with innovative drugs targeting COPD and influenza [6] - The company is advancing its clinical trials for various drugs, including a non-opioid pain relief medication, which aims to provide safer alternatives for pain management [6]

Group 1 - The core point of the news is that Health元药业集团股份有限公司 has applied for an "I class meeting" with the CDE, which is currently in processing status [1] - The I class meeting is typically held within 30 days after the application and addresses significant safety issues in drug clinical trials or major technical issues in the development of breakthrough therapies [1] - Health元药业集团股份有限公司 was established in 1992 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 1,874.20042 million RMB [1] Group 2 - The company has made investments in 31 enterprises and participated in 174 bidding projects, indicating active engagement in the market [1] - Health元药业集团股份有限公司 holds 893 trademark registrations and 156 patents, showcasing its focus on intellectual property [1] - The company has 106 administrative licenses, reflecting its compliance and operational capabilities [1] Group 3 - Major shareholders of Health元药业集团股份有限公司 include Shenzhen百业源投资有限公司 with a 48.96% stake, Hong Kong Central Clearing Limited with 3.74%, and others [2] - The ownership structure indicates a significant concentration of ownership with the largest shareholder holding nearly half of the company [2]

Financial Performance - Health元 reported a total revenue of 7.898 billion yuan for the first half of 2025, a decrease of 4.08% year-on-year [1] - The net profit attributable to shareholders was 785 million yuan, reflecting a year-on-year increase of 1.1% [1] - The gross margin was 62.21%, down 1.75% from the previous year, while the net margin increased by 8.41% to 22.33% [1] - Total operating expenses were 2.217 billion yuan, accounting for 28.07% of revenue, a decrease of 4.41% year-on-year [1] - Earnings per share rose to 0.43 yuan, a 2.38% increase compared to the previous year [1] Business Evaluation - The company's return on invested capital (ROIC) for the previous year was 9.39%, indicating average capital returns [2] - The net profit margin was reported at 19.1%, suggesting a high added value for the company's products or services [2] - The company has experienced two loss years since its IPO, indicating a relatively fragile business model [2] Accounts Receivable - The accounts receivable to profit ratio has reached 208.16%, suggesting a need for attention to the company's accounts receivable situation [3] Fund Holdings - The largest fund holding in Health元 is the Guolian An Small Cap Selected Mixed Fund, which has increased its holdings to 4.355 million shares [4] - The fund's recent performance shows a 37.7% increase over the past year [4] Innovation Pipeline - The company has over 20 first-class innovative drugs in development, with more than 10 in key research stages [5] - The innovative drug pipeline includes a new oral PREP inhibitor for COPD, which has completed Phase I clinical trials and is advancing to Phase II [6] - The company is also developing a pediatric formulation of its flu drug, aimed at improving acceptance among children [10] Internationalization Strategy - The company is focusing on internationalization, with plans to establish sales subsidiaries in the Netherlands and the Philippines [13] - A strategic partnership has been formed with Kalbe Group in Indonesia to set up a raw material drug factory targeting high-end markets [13] Shareholder Returns - The company has completed a share buyback plan totaling 2.7 billion yuan over the past five years and has increased cash dividends by nearly 10% year-on-year [14]

Fundraising Overview - The company raised a total of RMB 200,000.00 million through a share placement, with actual funds raised amounting to RMB 171,599.38 million after deducting issuance costs of RMB 4,625.36 million, resulting in a net amount of RMB 166,974.02 million [1][5] - As of June 30, 2025, the company has utilized RMB 171,655.28 million of the raised funds, with RMB 4,865.02 million used in the first half of 2025 [1][5] - The balance of the fundraising account as of June 30, 2025, is RMB 947.31 million, primarily held in dedicated fundraising accounts [1][5] GDR Issuance - The company issued Global Depository Receipts (GDR) corresponding to 63,825,000 shares, raising approximately USD 9,204 million, with a net amount of about USD 8,930 million after deducting underwriting and bank fees [1][5] - As of June 30, 2025, the GDR fundraising account balance is USD 9,766.53 million, including interest income of USD 1,087.17 million [1][5] Fund Management - The company has established a fundraising management system to ensure that the funds are used specifically for their intended purposes, with strict approval processes in place [1][5] - Funds are stored in dedicated accounts approved by the board, and a tripartite supervision agreement has been signed with the sponsoring institution and banks [1][5] Fund Utilization - In the first half of 2025, the company used RMB 4,865.02 million of the raised funds, with approximately 70% allocated for global R&D and industrialization plans, 10% for global sales and service network development, and 20% for working capital and other general corporate purposes [1][5] - The company has replaced RMB 21,532.82 million of self-raised funds with the raised funds for investment projects, complying with legal requirements [1][5] Project Changes - The company has changed the use of funds from the Zhuhai Health Industry Base project to new product R&D, expansion of the Haibin Pharmaceutical Pingshan base, and information technology platform projects due to changes in project feasibility and market conditions [1][5] - The company plans to return RMB 3,386.29 million from the sale of land use rights related to the Zhuhai project to the fundraising account for new product R&D [1][5] Compliance and Disclosure - The company has complied with relevant regulations regarding the disclosure of fundraising storage and utilization, with no violations reported [1][5]

Core Views - Joincare Pharmaceutical Group Industry Co., Ltd. reported a steady growth trajectory in its overall performance during the first half of 2025, demonstrating strong operational resilience despite market fluctuations and intensified competition [16][18]. Financial Highlights - Revenues for the reporting period were RMB 7,898,328,250.41, a decrease of 4.08% compared to the same period last year [4]. - Total profit increased by 4.58% to RMB 2,072,742,025.46 [4]. - Net profit attributable to shareholders of the listed company was RMB 784,939,913.34, reflecting a slight increase of 1.10% [4]. Company Profile and Major Financial Indicators - The company is engaged in R&D, production, and sales of pharmaceutical products, including chemical pharmaceuticals, biologics, and traditional Chinese medicine [5]. - The company has established a comprehensive end-to-end system covering the entire value chain, from R&D to sales [5]. Industry Overview - The Chinese pharmaceutical innovation sector is undergoing structural changes, with a focus on innovative drug development, supported by government policies [13][15]. - The National Medical Products Administration approved over 20 Class 1 innovative drugs from January to May 2025, marking a record high [13]. Business Model - The company employs a multi-pronged R&D model that integrates independent innovation, external licensing, and collaborative development [5]. - The company has established long-term partnerships with suppliers to ensure procurement efficiency and quality [6]. Performance Drivers - The health care products segment achieved a 35% increase in sales, becoming a key driver of performance [20]. - The respiratory therapeutic area saw a sales increase of 112% for Tobramycin Inhalation Solution, demonstrating strong growth momentum [19]. R&D Innovation - The company has established a pipeline of more than ten Category I innovative drugs, focusing on respiratory diseases and other therapeutic areas [23]. - Significant progress has been made in various therapeutic areas, including autoimmune diseases and metabolism [24][25]. Internationalization Strategy - The company is expanding its global footprint with the construction of its first overseas API plant in Jakarta, Indonesia [30]. - The company has successfully obtained regulatory approvals in multiple international markets, enhancing its global supply chain [30]. Future Outlook - The company plans to deepen R&D in innovative drugs, focusing on core strengths in respiratory, anti-infective, and gastroenterology fields [32]. - The company aims to optimize production processes and enhance efficiency through intelligent manufacturing and AI data analytics [33].

Core Viewpoint - Health元药业集团 reported a stable overall business performance in the first half of 2025, with core business segments working collaboratively to adapt to market changes and maintain resilience [3][4]. Financial Performance - Total assets at the end of the reporting period were CNY 35,552.22 million, a decrease of 0.46% from the previous year [1]. - Operating revenue was CNY 7,898.33 million, down 4.08% year-on-year [1]. - Total profit reached CNY 2,072.74 million, an increase of 4.58% compared to the previous year [1]. - Net profit attributable to shareholders was CNY 769.81 million, showing a slight increase of 1.04% from the previous year [1]. Business Segments - The respiratory product segment faced sales declines due to continued centralized procurement policies and intensified market competition, but the company managed to grow sales of its existing products, such as tobramycin inhalation solution, by 112% year-on-year [4]. - The health products segment performed well, achieving a growth of 35% year-on-year, highlighting the positive effects of diversified business strategies [4]. - The raw materials segment maintained strong competitiveness, with key products like 7-ACA sustaining good pricing [4]. R&D and Innovation - The company has made significant progress in R&D across various therapeutic areas, with over 10 innovative drugs in the respiratory field, including a new treatment for influenza that has entered the production application stage [5][6]. - In the autoimmune field, a humanized monoclonal antibody for moderate to severe psoriasis has completed Phase III clinical trials, showing superior efficacy compared to existing treatments [6]. - The company is also advancing in the pain management area with a non-opioid innovative drug that has completed Phase I clinical trials [7]. International Expansion - The company has commenced construction of its first overseas raw material drug factory in Jakarta, Indonesia, aimed at enhancing its global supply chain and market responsiveness [8]. - Regulatory approvals for production and import in the Philippines and Malaysia have been achieved, facilitating market entry in Southeast Asia [8]. - The company is pursuing a strategic acquisition of a Vietnamese company to enhance its market penetration in the region [8].

Core Viewpoint - The board of directors of Health元药业集团 has convened to approve several key reports and proposals during its twelfth meeting of the ninth session, emphasizing the company's commitment to transparency and governance [1][2][3]. Group 1: Meeting Details - The meeting was held on August 22, 2025, in Shenzhen, with all nine directors present, along with members of the supervisory board and senior management [1]. - The meeting was chaired by Chairman Zhu Baoguo and conducted via a combination of in-person and video conferencing [1]. Group 2: Resolutions Passed - The board approved the 2025 semi-annual report and its summary, which will be published on August 23, 2025, across various platforms [1]. - The board also approved the special report on the storage and actual use of raised funds for the first half of 2025, with unanimous support [2]. - A mid-year evaluation report on the "Quality Improvement and Efficiency Enhancement Action Plan" was also approved, reflecting the company's ongoing strategic initiatives [2]. - The board passed a resolution to amend certain provisions of the company's sustainable development system, which has been reviewed by the sustainability committee [3]. - Additionally, the board approved amendments to the anti-corruption and anti-commercial bribery policy, also reviewed by the sustainability committee [3].

Group 1 - The Supervisory Board of the company reviewed the 2025 semi-annual report and its summary, concluding that the preparation and review procedures comply with relevant laws, regulations, and internal management systems [2] - The content and format of the semi-annual report and its summary meet the requirements of the China Securities Regulatory Commission and the Shanghai Stock Exchange, accurately reflecting the company's operational management and financial status for the first half of 2025 [2] - The Supervisory Board confirmed that the personnel involved in the preparation and review of the semi-annual report did not violate confidentiality regulations [2] Group 2 - The Supervisory Board conducted a special report review on the management and actual use of raised funds for the first half of 2025, finding that the management and use of raised funds comply with regulatory requirements and the company's fundraising management system [2] - The use of raised funds was deemed legal and compliant, with no violations of laws or regulations that could harm shareholder interests identified [2]

《公司章程》和公司内部管理制度的各项规定，半年报及其摘要的内 容和格式符合中国证监会及上海证券交易所的各项规定，所包含的信息能够从各方 面真实地反映公司 2025 年半年度的经营管理及财务状况，参与半年报编制和审议的 人员无违反保密规定的行为。 证券代码：600380 证券简称： 健康元 公告编号：临 2025-059 健康元药业集团股份有限公司 九届监事会九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健康元药业集团股份有限公司（以下简称：本公司）九届监事会九次会议于 2025 年 8 月 12 日（星期二）以电子邮件并电话确认的方式发出会议通知并于 2025 年 8 月 22 日（星期五）公司九届董事会十二次会议结束后在健康元药业集团大厦 2 号会 议室以现场加视频会议形式召开。本次会议由监事会召集人余孝云召集并主持，应 参加监事三人，实际参加监事三人，会议的召开符合《公司法》及《公司章程》的 规定。本次会议以记名投票方式审议并通过以下议案： 一、审议并通过《对 <健康元药业集团股份有限公司 ensp=" ...

健康元药业集团 反腐败反商业贿赂制度 健康元药业集团股份有限公司 反腐败反商业贿赂制度 （经公司 2025 年 8 月 22 日召开的九届董事会十二次会议修订） 第一章 总则 第一条 为预防生产经营管理中的腐败，切实做好反商业贿赂、反腐败工作， 加强集团内控，强化制度监督与反腐，加强对重点、关键岗位的人员监督，确保 反腐败反商业贿赂长期有效，防止各种违法乱纪等不正当行为的发生，特制定本 制度。 第二条 本制度适用于集团总部及下属所有全资企业、控股企业和分公司（以 下统称：集团）。 第三条 集团一切生产经营管理活动或对外联活动，均应严格遵守本制度。 本条例中的活动包括但不限于与政府部门的接触、与客户代表洽谈订单、原材料 的采购、工程施工、产品销售、设备采购和维护等经济活动。 第四条 所有与集团有业务往来的客户、供应商、服务商、承包商均在本制 度管辖范围。 第二章 职责 第五条 集团风险管理部为集团反腐败反商业贿赂的监督管理部门。 第六条 监督管理部门的主要职责： （一）遵照国家有关政策、法律、法规及集团规章制度，开展集团反腐败、 反商业贿赂工作； （二）加强重要岗位、重要环节工作人员廉洁从业的管理和监督，在源头 ...